Private Label Tranexamic & Kojic Acid Face Cream Low MOQ

The realistic minimum order quantity for a private label face cream containing tranexamic acid and kojic acid is 100 to 500 units for most contract manufacturers who specialize in brightening formulations. The exact floor depends on three variables: whether you use a stock (off-the-shelf) base formula, the packaging format you choose, and where the manufacturer is located. Stock-formula programs — where the manufacturer already has a validated brightening cream and simply fills it into your branded packaging — routinely accept 100–200 units. These programs exist because the development cost has already been amortized across many clients. Custom formula development, where a cosmetic chemist creates a unique active concentration or texture for your brand, almost always requires 500 units minimum because the R&D, stability testing, and challenge testing costs need to be spread across a larger run to keep per-unit economics viable. Packaging format also moves the MOQ. Stock jars or airless pumps that a manufacturer already stocks allow smaller runs; custom-tooled components — embossed caps, bespoke jar shapes, custom color closures — require tooling amortization that pushes MOQs to 500–1,000 units and adds $500–$2,500 in one-time tooling fees. Geography matters too. Domestic US and EU manufacturers tend to have higher MOQs (500–1,000) but shorter lead times and easier regulatory alignment. Asian contract manufacturers (South Korea, China, India) often accept 200–300 unit MOQs and price competitively, but add 4–6 weeks for international shipping and require you to conduct your own regulatory review for your target market. A common mistake first-time founders make is negotiating the MOQ without confirming it includes labeling, filling, and capping — not just the bulk cream. Always request an all-in quote that covers bulk manufacturing, filling, capping, labeling, and quality-release documentation. AJ Cosmo Labs lets you post a brief that specifies your MOQ ceiling and surfaces only manufacturers who can meet it, saving you from hours of back-and-forth.

The total timeline from initial brief to finished, retail-ready private label brightening cream — one containing tranexamic acid and kojic acid — runs 8 to 16 weeks for most founders, and the range is wide for specific, avoidable reasons. Weeks 1–2 cover briefing and supplier selection. This is the time you spend writing your formulation brief (target actives, texture, pH range, regulatory scope, MOQ, packaging format), sending it to shortlisted manufacturers, evaluating responses, signing an NDA, and issuing a purchase order or development deposit. Founders who skip a detailed brief add 2–3 weeks of revision cycles before development even starts. Weeks 3–5 are the formulation development phase. The cosmetic chemist builds the prototype emulsion, adjusts pH for kojic acid stability (target 3.5–5.5), and tests initial appearance, skin-feel, and active dispersion. For a stock-base program this phase is as short as one week; for a fully custom formula it's 3–4 weeks. Weeks 6–8 involve prototype review and iteration. You receive physical samples, evaluate texture, scent, spreadability, and color — then request adjustments. One iteration round is normal; two is common if the texture or active odor profile needs correction. Weeks 9–11 are stability and challenge testing. Accelerated stability at 40 °C / 75% RH for a minimum of 4–8 weeks is the industry standard before launch. Some manufacturers run stability in parallel with prototype revisions to compress this phase. ISO 11930 or USP 51 microbial challenge testing also happens here and typically takes 28 days. Skipping or shortening stability testing is the single most common mistake founders regret later — a formula that separates or browns on shelf 6 months after launch destroys both customer trust and retail relationships. Weeks 12–14 cover production filling, labeling, and QC release. The manufacturer fills, caps, and labels your order, then issues a certificate of conformance and batch records. Allow 1–2 weeks for domestic freight or 3–5 weeks for international shipping on top of this. AJ Cosmo Labs helps compress the early weeks by connecting you with manufacturers who already specialize in brightening actives, so you're not educating a generalist on tranexamic acid stability requirements from scratch.

Effective use concentrations for tranexamic acid in leave-on skincare are typically 2–5% by weight. The published clinical literature — including studies from Korean and Japanese dermatology journals — most frequently uses 3% tranexamic acid for measurable reduction in melanin index after 8–12 weeks of twice-daily use. Stock private-label formulas commonly land at 2–3% to balance efficacy with cost-of-goods impact, since tranexamic acid is a mid-priced active at roughly $15–$40 per kilogram depending on grade and supplier. Kojic acid is more constrained by both efficacy and regulation. At concentrations below 0.5% it shows minimal brightening activity; at concentrations above 2% it becomes a significant sensitizer risk for many skin types. The EU's Scientific Committee on Consumer Safety (SCCS) has set a leave-on maximum of 1% kojic acid in face products (0.5% for hand products), which effectively sets a global ceiling for brands selling into multiple markets. The functional sweet spot is 0.5–1% for a leave-on face cream that is both effective and globally compliant. Formulators often add supporting brightening actives — niacinamide at 4–5%, alpha-arbutin at 1–2%, or sodium ascorbyl phosphate at 2–3% — to build on the melanogenesis-inhibiting effects of the duo without pushing kojic acid above its regulatory ceiling. This layered approach also gives your cosmetic chemist clinical story material for marketing. PH management is critical: kojic acid degrades and browns above pH 5.5, and its activity drops sharply above pH 6. A well-formulated brightening cream keeps the final pH at 4.0–5.0, which is also comfortable for the skin barrier and compatible with tranexamic acid. For regulatory purposes, neither ingredient has an approved OTC drug claim in the US. Avoid language like 'treats melasma' or 'clinically proven to remove dark spots' without clinical trial data specific to your finished formula — such claims risk FDA warning letters. AJ Cosmo Labs connects you with cosmetic chemists who understand both the formulation science and the regulatory copy guardrails.

Launching a private label brightening cream brand — even at low MOQ — requires accounting for several cost buckets that first-time founders routinely undercount. Formulation and development costs range from $0 to $3,000. A pure stock-formula program has no development fee because the formulation work is already done. A lightly customized formula (fragrance change, texture adjustment) may carry a $500–$1,500 development fee that is often credited back against the first production order. A fully bespoke formula with custom active concentrations and your own stability study runs $2,000–$5,000+ in development before a single unit is filled. Manufacturing unit costs for a brightening face cream with tranexamic acid and kojic acid at 100–500 unit MOQs typically fall between $5 and $18 per finished unit (filled, capped, labeled). The wide range reflects formula complexity, active-ingredient cost, packaging selection, and manufacturer location. A 30 ml airless pump with premium ingredients at 200 units from a US manufacturer will cost more than a 50 ml screw-cap jar at 500 units from a Korean ODM. Packaging tooling for custom components adds $500–$2,500 as a one-time cost. If you use the manufacturer's stock packaging with your own label, this cost is zero. Stability and testing fees, if not bundled by the manufacturer, run $300–$800 for accelerated stability and $400–$700 for ISO 11930 microbial challenge testing. Some low-MOQ manufacturers include these in their program cost; ask explicitly. Third-party regulatory review — safety assessment, INCI declaration audit, and an EU Responsible Person appointment if you're selling into Europe — costs $600–$2,000 depending on scope. Branding, photography, and e-commerce setup sit outside manufacturing but are real costs: budget $500–$3,000 for logo/label design, $300–$1,000 for product photography, and $30–$300/month for a Shopify or similar storefront. Total startup outlay for a founder launching at 200 units with a stock formula, basic custom label, and domestic US manufacturer realistically runs $3,000–$8,000 all-in. Scaling to 500 units with a custom formula and professional branding runs $8,000–$20,000. AJ Cosmo Labs helps you get competitive quotes across multiple manufacturers through a single brief so you can compare these buckets before committing.

Kojic acid is legal as a cosmetic ingredient in both the United States and the European Union, but the EU imposes a concentration restriction that US regulations do not, making market selection a critical formulation decision. In the United States, the FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act. Kojic acid has no approved OTC monograph and is not a restricted ingredient under US cosmetic law. A face cream with kojic acid at any concentration used in a reasonable cosmetic context — without drug claims like 'treats melasma' — is lawful for US sale. The practical formulation ceiling is around 2% from an efficacy and sensitization risk standpoint, not a regulatory one. In the European Union, the situation is more tightly defined. The SCCS evaluated kojic acid in 2021 (SCCS/1622/21) and deemed it safe at a maximum of 1% in face products and 0.5% in body/hand products for leave-on use. This assessment was incorporated into Annex III of EU Cosmetic Regulation 1223/2009, making 1% the hard ceiling for leave-on face creams sold across the EU and EEA. The same limits apply to Great Britain post-Brexit under OPSS oversight. Brands manufacturing above 1% for the US market and seeking EU expansion must reformulate — there is no waiver process. From a safety science perspective, kojic acid at 0.5–1% is generally well tolerated. The primary adverse effects documented are contact sensitization and, at higher concentrations, erythema in sensitive skin types. Patch testing is advisable before regular use. Including a sensitization disclaimer in your product directions is good practice and may be required by some retail channels. Transexamic acid has no regulatory restriction in either market when used as a cosmetic active (i.e., without a drug claim). It is not a known sensitizer at cosmetic use levels and has a clean safety profile at 2–5%. For a brand planning simultaneous US and EU launch, the pragmatic formulation is 1% kojic acid and 3% tranexamic acid — fully compliant globally and clinically relevant in both markets. Cosmetic chemists connected through AJ Cosmo Labs routinely formulate for multi-market compliance from the first prototype.

Finding a contract manufacturer that is genuinely equipped to handle a brightening cream with dual actives like tranexamic acid and kojic acid — rather than a general-purpose white-label filler who will simply blend your spec without understanding the chemistry — requires a structured vetting process. Start with a written formulation brief before approaching any manufacturer. The brief should specify: target actives and concentration ranges, finished product pH target, packaging format and fill weight, target markets (US only, EU, global), MOQ and budget per unit, any restricted ingredient lists (e.g., no parabens, vegan), required testing (stability, challenge, patch), and your launch timeline. Manufacturers who respond to a detailed brief with thoughtful, specific questions are almost always more capable than those who immediately send a generic price list. Request a formulation capabilities deck and active-ingredient experience list. A manufacturer who has run tranexamic acid or kojic acid formulations before will have stability data, existing validated base formulas, and raw material supplier relationships. Ask specifically: 'Have you manufactured a kojic acid face cream compliant with EU Annex III limits?' A confident yes with documentation is a green flag; a vague yes without supporting evidence is not. Verify GMP compliance. US manufacturers should hold an FDA Cosmetic Facility Registration (required under the Modernization of Cosmetics Regulation Act of 2022, MoCRA). EU-supplying manufacturers should operate under ISO 22716 Cosmetics GMP. Ask for their most recent GMP audit report. Request references from brands they've manufactured brightening SKUs for — actual brands you can look up and contact, not just logos on a slide deck. Red flags to watch for: no NDA offered before sharing your formula; reluctance to provide COAs on raw materials; inability to explain the pH rationale for kojic acid stability; no in-house stability testing capability (outsourcing is fine but should be disclosed); quoted lead times below 8 weeks for a new formula (physically impossible if real stability testing is included). AJ Cosmo Labs is designed specifically to address the vetting gap. Every manufacturer listed on the platform has been reviewed before activation, and the iOS app lets you post your brief once and receive responses from multiple suppliers who already specialize in skin-active formulations. You can compare MOQs, lead times, and capabilities side by side, message suppliers directly, and manage sample tracking — all without managing a chaotic email thread. Download the app on the App Store and post your brightening cream brief to get started.

Packaging selection for a kojic acid face cream is not purely aesthetic — it directly affects active-ingredient stability and shelf life, and the wrong choice can cause your formula to brown or lose potency before it reaches the consumer. Kojic acid is photo-sensitive and oxidizes readily in the presence of air and light. This makes opaque, airless packaging the gold standard for a brightening cream containing this active. Airless pump bottles (15–50 ml) are the most recommended primary packaging because they eliminate headspace air, prevent light exposure, and deliver a precise metered dose. They also read as premium to the consumer, which supports higher retail price points consistent with an active-ingredient-focused SKU. Opaque jars with an inner PP seal disc are acceptable for formulas with antioxidant co-actives (tocopherol, sodium ascorbyl phosphate) that buffer the kojic acid against oxidation. Clear glass or transparent PET jars are not recommended — UV and visible light degradation will cause color shift within 3–6 months of manufacture even with accelerated stability passing at launch. For packaging materials, PCR (post-consumer recycled) plastic is increasingly expected by retail buyers and DTC consumers, and does not negatively affect formula stability. Aluminum tubes are another option for a brightening balm-style texture and offer excellent barrier protection. Fill weights that perform best commercially for premium brightening face creams are 30 ml and 50 ml. Below 30 ml, the per-ml price feels high to consumers relative to the visible product. Above 50 ml, consumers hesitate on a first purchase of a brightening cream with unfamiliar actives. Component sourcing affects MOQ significantly. If your contract manufacturer stocks airless pumps in standard sizes (30 ml, 50 ml), your MOQ can stay as low as 100–200 units. Custom-molded or custom-colored components require tooling, which adds cost and raises the practical MOQ to 500–1,000 units. A good starting strategy for low-MOQ launches is to use a manufacturer's stock pump or jar with a premium custom label — this keeps economics viable at 200 units while still delivering a branded, shelf-ready product. AJ Cosmo Labs allows you to specify your packaging preferences in your brief so manufacturers can quote you on realistic MOQs before you're deep into negotiations.